APA (7th ed.) Citation

Pasvolsky, O., Milton, D. R., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., . . . Qazilbash, M. H. (2025). Daratumumab-Based Second Line Therapy Improves Outcomes after VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance. Transplantation and cellular therapy, 31(2), S421. https://doi.org/10.1016/j.jtct.2025.01.644

Chicago Style (17th ed.) Citation

Pasvolsky, Oren, et al. "Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance." Transplantation and Cellular Therapy 31, no. 2 (2025): S421. https://doi.org/10.1016/j.jtct.2025.01.644.

MLA (9th ed.) Citation

Pasvolsky, Oren, et al. "Daratumumab-Based Second Line Therapy Improves Outcomes After VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance." Transplantation and Cellular Therapy, vol. 31, no. 2, 2025, p. S421, https://doi.org/10.1016/j.jtct.2025.01.644.